Minor salivary gland carcinomas of oral cavity and oropharynx

2009 ◽  
Vol 123 (S31) ◽  
pp. 52-57 ◽  
Author(s):  
H Chijiwa ◽  
K Sakamoto ◽  
H Umeno ◽  
T Nakashima ◽  
G Suzuki ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Salivary Gland ◽  
Oral Cavity ◽  
Cell Carcinoma ◽  
Minor Salivary Gland ◽  
Survival Rates ◽  
Salivary Gland Carcinoma ◽  
Patients With Cancer ◽  
Significant Difference ◽  
Gland Carcinoma

AbstractThis paper reviews 22 cases of minor salivary gland carcinoma of the oral cavity or oropharynx which were treated at Kurume University Hospital between 1976 and 2005. Minor salivary gland carcinoma was observed in eight of 362 patients with cancer of the oral cavity (2 per cent), and in 14 of 275 patients with cancer of the oropharynx (5 per cent). The five-year and 10-year survival rates of patients with oropharyngeal minor salivary gland carcinoma were 90 per cent. No statistically significant difference was observed between survival rates for oropharyngeal minor salivary gland carcinoma and for oropharyngeal squamous cell carcinoma (p = 0.06). The five- and 10-year survival rates of patients with oral cavity minor salivary gland carcinoma were 75 and 37 per cent, respectively. No statistically significant difference was observed between survival rates for oral cavity minor salivary gland carcinoma and oral cavity squamous cell carcinoma.Patients' survival results correlated well with the clinical stage of their lesions. A significant difference in survival was observed, comparing stage IV with stages I, II and III (p = 0.04). In contrast, no significant relationship was found between either survival and tumour type or survival and treatment. Adjuvant therapy is recommended for patients with grade III adenoid cystic carcinoma with perineural infiltration or intravascular infiltration.

scholarly journals Molecular detection of human papillomavirus-16 among Sudanese patients diagnosed with squamous cell carcinoma and salivary gland carcinoma

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Fatima E. Mohamed ◽  
Leena N. Aldayem ◽  
Maisa A. Hemaida ◽  
Omayma Siddig ◽  
Zeinab H. Osman ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Salivary Gland ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cancer Diagnosis ◽  
Molecular Detection ◽  
Salivary Gland Carcinoma ◽  
Hpv 16 ◽  
Gland Carcinoma

Abstract Objective Human papillomavirus (HPV) gained momentum as a potential etiological factor for many types of cancers. Therefore, the aim of this study was to assess the prevalence of HPV-16 infection among Sudanese patients diagnosed with Squamous Cell Carcinoma (SCC) and Salivary Gland Carcinoma. A descriptive, hospital-based study was conducted. 150 formalin-fixed paraffin-embedded blocks were collected. Results The study population included a total of 150 patients aged between 18 to 87 years with a mean age of 48.8 ± 11.9 years. Based on gender, females constituted 46.7% while males constituted 53.3%. The 150 patients were classified into 40 (26.0%) esophageal, 30 (20.0%) nasopharyngeal, 18 (12.0%) conjunctival, 18 (12.0%) tongue 12 (8.0%) laryngeal, 8 (5.3%) lip, 6 (4.0%) oropharyngeal, 6 (4.0%) mucoepidermoid, and 6 (4.0%) adenoid cystic, and 6 (4.0%) myoepithelial carcinomas. Odds ratio for male and female diagnosed with carcinoma was 1.025 [0.439–2.394, 95% CI]. Molecular detection of HPV-16 revealed a prevalence of 26 (17.3%) patients were positive for HPV-16. According to cancer diagnosis, esophageal SCC patients showed a high proportion of HPV-16; 14/40 (35.0%). A statistically significant difference was seen for the distribution of HPV-16 positive patients based on cancer diagnosis, P value 0.001.

Prognostic factors in patients with minor salivary gland carcinoma of the oral cavity and oropharynx

Head & Neck ◽  
2010 ◽  
Vol 33 (10) ◽  
pp. 1406-1412 ◽  
Author(s):  
José F. Carrillo ◽  
Federico Maldonado ◽  
Liliana C. Carrillo ◽  
Margarita C Ramirez-Ortega ◽  
Juan G. Gómez Pizano ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Prognostic Factors ◽  
Oral Cavity ◽  
Minor Salivary Gland ◽  
Salivary Gland Carcinoma ◽  
Gland Carcinoma

SP159 – Survival in oral cavity minor salivary gland carcinoma

2009 ◽  
Vol 141 (3) ◽  
pp. P164-P164
Author(s):  
Kiran Kakarala ◽  
Neil Bhattacharyya
Keyword(s):  
Salivary Gland ◽  
Oral Cavity ◽  
Minor Salivary Gland ◽  
Salivary Gland Carcinoma ◽  
Gland Carcinoma

Survival in oral cavity minor salivary gland carcinoma

2010 ◽  
Vol 143 (1) ◽  
pp. 122-126 ◽  
Author(s):  
Kiran Kakarala ◽  
Neil Bhattacharyya
Keyword(s):  
Salivary Gland ◽  
Oral Cavity ◽  
Minor Salivary Gland ◽  
Salivary Gland Carcinoma ◽  
Gland Carcinoma

scholarly journals Low-dose aspirin confers a survival benefit in patients with pathological advanced-stage oral squamous cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sheng-Dean Luo ◽  
Shao-Chun Wu ◽  
Wei-Chih Chen ◽  
Ching-Nung Wu ◽  
Tai-Jan Chiu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Oral Cavity ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cox Regression ◽  
Survival Rates ◽  
Distant Metastases ◽  
Good Prognosis ◽  
High Rate

AbstractOral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.

Tumor progression and chemoradiosensitivity in relation to the expression of apoptosis related proteins in esophageal squamous cell carcinoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4588-4588
Author(s):  
S. Tsujitani ◽  
H. Saito ◽  
S. Tatebe ◽  
M. Ikeguchi
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Survival Rates ◽  
Mutant P53 ◽  
Survivin Mrna ◽  
P53 Expression ◽  
Significant Difference ◽  
Related Proteins

4588 To study apoptosis related protein expression and their impact on patient’s survival time and sensitivity to postoperative chemoradiotherapy (CRT), we examined the expression of RB, mutant p53, MDM2 and Bax proteins using immunohistochemistry in 115 (CRT; 42) surgically resected esophageal squamous cell carcinoma (ESCC). We also investigated the survivin mRNA expression with quantitative analysis by real-time RT-PCR in 57 (CRT; 30) patients with ESCC. CRT contained 40–60 Gy radiation and continuous infusion of 5-FU (300mg/sqm, day1–5qw). Expression of RB, mutant p53, MDM2, Bax proteins and survivin mRNA were detected in 65%, 46%, 33%, 37% and 32% of patients, respectively. Patients with RB(+), MDM2(-), Bax(+) or survivin(-) tumor had significantly better survival rates than those with RB(-), MDM2(+), Bax(-) or survivin(+) tumor, respectively. However, there was no significant difference in survival between patients with and without mutant p53 expression. In patients not treated with CRT, those with RB(+) or survivin(-) tumor survived significantly longer than those with RB(-) or survivin(+) tumor, respectively. In patients treated with CRT, the expression of Bax protein and survivin mRNA was prognostic indicator. The 5-year survival rates of patients with Bax(+) and survivin(-) tumors were 65% and 39%, significantly superior to 21% and 0% of those with Bax(-) and survivin(+) tumors (P<0.05 and P<0.01, respectively). These results indicate that the expression levels of apoptosis related proteins are important for predicting the prognosis of ESCC patients. Furthermore, CRT may be effective in patients with Bax(+) or survivin(-) tumors. Further investigations are required for clarifying the relationship between the efficacy of postoperative CRT and apoptosis promoting status of ESCC. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document